Clinical trial
Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
NCT05403333 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 10, 2022
- Completion date
- March 9, 2025
- Enrollment
- 61 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
breast neoplasms, locally advanced or metastatic breast cancer